Choose your Region

Are you sure you want to proceed?

You will be leaving the Cook Medical website that you were viewing and going to a Cook Medical website for another region or country. Not all products are approved in all regulatory jurisdictions. The product information on these websites is intended only for licensed physicians and healthcare professionals.

Search Cook Medical

Surgery
October 9th, 2017

Highlights from the Zenapro multicenter data


Clinical data on the Zenapro® Hybrid Hernia Repair Device is now published in the journal Surgical Endoscopy.

You can read the study here.

This clinical study followed 63 patients who had a ventral-hernia repair procedure. These patients had a mean BMI of 34.5 kg/m2, and most of them had at least one comorbidity. Many patients had a history of smoking. There were four recurrences. One year after the procedure, 55 patients were available for follow-up.

According to the study, Zenapro had a recurrence rate of 7.3% at one year follow-up.

Brent, a Cook Surgery global product manager, was not surprised by these results. “Zenapro is a hybrid, which means it’s a combination of two components,” he says. “Those components are polypropylene and a biomaterial called small intestinal submucosa (SIS). Polypropylene is already trusted by many surgeons. And, the biomaterial has been used in our products, like the Biodesign Hernia Graft, for more than a decade. We aren’t surprised to see that the combination of polypropylene and SIS is associated with an acceptable recurrence rate.”

Learn more about Zenapro.

Get product specs and order information or read some current trends in abdominal wall reconstruction.

 

Note: After accounting for the patients that were lost to follow up, the recurrence rate was updated to 7.3% in the erratum of the paper.

Bittner JG 4th, El-Hayek K, Strong AT, et al. First human use of hybrid synthetic/biologic mesh in ventral hernia repair: a multicenter trial. Surg Endosc. 2017. doi: 10.1007/s00464-017-5715-6.